+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The tyrosine kinase associated with the bombesin receptor complex: Evidences for autocrine activation in small cell lung carcinomas



The tyrosine kinase associated with the bombesin receptor complex: Evidences for autocrine activation in small cell lung carcinomas



Lung Cancer 4(3-4): 190-195




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 062015174

Download citation: RISBibTeXText

DOI: 10.1016/s0169-5002(88)80045-x


Related references

Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas. Proceedings of the National Academy of Sciences of the United States of America 85(7): 2166-2170, 1988

Autocrine activation of the tyrosine kinase associated with the bombesin receptor in small cell lung carcinoma. Journal Of Cellular Biochemistry Supplementrt A: 103, 1988

Deregulation of the tyrosine kinase associated with the bombesin receptor in small cell lung carcinomas. European Journal of Cancer and Clinical Oncology 23(11): 1752, 1987

A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas. Annals of the new York Academy of Sciences 547: 293-302, 1988

Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. Lung Cancer 43(2): 135-143, 2004

A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. Biochemical & Biophysical Research Communications 156(3): 1383-1389, 1988

Apoptotic sensitization in non-small cell lung cancer cells through tyrosine kinase inhibition Possible role for cytokine signaling and non-receptor tyrosine kinases as regulators of caspase activation and NSCLC cell survival. Proceedings of the American Association for Cancer Research Annual Meeting 42: 131, 2001

Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 109(4): 741-750, 2007

ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Annals of Surgical Oncology 20(1): 200-208, 2013

Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Molecular and Clinical Oncology 2(5): 725-730, 2014

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. International Journal of Clinical Oncology 19(4): 594-600, 2014

Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. Journal of Thoracic Oncology 3(8): 832-839, 2008

Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells. Cancer Letters 162(1): 87-95, 2001

Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells. Cancer Letters 162(1): 87-95, 2001

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget 6(28): 24904-24911, 2015